Clinical Review
2019 Update on fertility
OBG Management. 2019 February;31(2):18-24
February 5, 2019|ObGyn
Author and Disclosure Information
Progress is being made in recognizing infertility as a disease (thus meriting insurance coverage) and in improving embryo selection techniques for IVF treatment, but more work is needed. Plus, the SART's redesigned report includes a new feature for calculating a personalized prognosis that can aid in treatment decision making. Two fertility experts boil down these complex issues.
With all the above considerations, the ASRM has appropriately concluded that "the value of preimplantation genetic testing for aneuploidy (PGT-A) as a screening test for IVF patients has yet to be determined."11
WHAT THIS EVIDENCE MEANS FOR PRACTICE
Standardization of clinical and laboratory protocols and additional studies to assess the effects of PGT-A on live birth rates per initiated cycles are recommended before this new technology is widely adopted in routine clinical practice. In our practice, we routinely offer and perform extended culture to blastocyst stage and standard morphologic assessment. After a thorough counseling on the current status of PGT-A, about 15% to 20% of our patients opt to undergo PGT-A.
,falseStandardization of clinical and laboratory protocols and additional studies to assess the effects of PGT-A on live birth rates per initiated cycles are recommended before this new technology is widely adopted in routine clinical practice. In our practice, we routinely offer and perform extended culture to blastocyst stage and standard morphologic assessment. After a thorough counseling on the current status of PGT-A, about 15% to 20% of our patients opt to undergo PGT-A.
